DiaSorin SpA engages in developing, producing and marketing reagent kits for laboratory diagnostics. The company is headquartered in Saluggia, Vercelli and currently employs 3,280 full-time employees. The company went IPO on 2007-07-19. The firm specializes in provision of developing, producing and commercializing reagent kits for the in vitro diagnostics. The firm develops and manufactures reagents for in vitro diagnostics and produces products for the fields of infectious disease, hepatitis, endocrinology, bone & mineral metabolism, cancer, brain injury, cardiac, therapeutic drug monitoring and autoimmunity. The Company’s business activities are divided into two markets. The Immunodiagnostics market develops, produces and markets immunoreagent kits, which are based on three techniques: Chemiluminescence (CLIA), Colorimetry (ELISA) and Radioimmunometry (RIA). The Molecular Diagnostics market supplies end laboratories with an automated result to perform the three steps for the final diagnostic result, including nucleic acids extraction, amplification and diagnosis. The company operates through ELISA immunodiagnostic business portfolio.
Follow-Up Questions
¿Quién es el CEO de DiaSorin SpA?
Mr. Carlo Rosa es el Chief Executive Officer de DiaSorin SpA, se unió a la empresa desde 1998.
¿Qué tal es el rendimiento del precio de la acción DSRLF?
El precio actual de DSRLF es de $94.25, ha decreased un 0% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de DiaSorin SpA?
DiaSorin SpA pertenece a la industria Health Care y el sector es Health Care
¿Cuál es la capitalización bursátil de DiaSorin SpA?
La capitalización bursátil actual de DiaSorin SpA es $5.2B
¿Es DiaSorin SpA una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 18 analistas han realizado calificaciones de análisis para DiaSorin SpA, incluyendo 4 fuerte compra, 7 compra, 6 mantener, 2 venta, y 4 fuerte venta
